Search Results | Blood | American Society of Hematology

1-20 of 54

2 3

Sort by

Sort Order Select

Journal Articles

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

Blood (2022) 139 (18): 2758–2769.

DOI: https://doi.org/10.1182/blood.2021014255

Published: 2022

Includes: Supplemental data

Journal Articles

TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 710.

DOI: https://doi.org/10.1182/blood-2021-145158

Published: 2021

Journal Articles

Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center

Blood (2021) 138 (Supplement 1): 2507.

DOI: https://doi.org/10.1182/blood-2021-151179

Published: 2021

Journal Articles

Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy

Blood (2021) 138 (Supplement 1): 1429.

DOI: https://doi.org/10.1182/blood-2021-149702

Published: 2021

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

DOI: https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)

Blood (2021) 138 (Supplement 1): 325.

DOI: https://doi.org/10.1182/blood-2021-149112

Published: 2021

Journal Articles

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Blood (2021) 138 (Supplement 1): 883.

DOI: https://doi.org/10.1182/blood-2021-147568

Published: 2021

Journal Articles

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

Blood (2021) 138 (Supplement 1): 4762.

DOI: https://doi.org/10.1182/blood-2021-150684

Published: 2021

Journal Articles

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

Jae H Park, Craig S. Sauter, M. Lia Palomba, Gunjan L Shah, Parastoo B Dahi, Richard J Lin, Michael Scordo, Connie Lee Batlevi, Miguel-Angel Perales, Peter Kane, Aishat Olaide Afuye, Elena Mead, Bianca Santomasso, Elizabeth Halton, Michel Sadelain, Renier J Brentjens

Blood (2021) 138 (Supplement 1): 96.

DOI: https://doi.org/10.1182/blood-2021-150431

Published: 2021

Journal Articles

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 827.

DOI: https://doi.org/10.1182/blood-2021-153204

Published: 2021

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

Blood (2021) 138 (Supplement 1): 1644.

DOI: https://doi.org/10.1182/blood-2021-153443

Published: 2021

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Benjamin Diamond, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Eric L Smith, MDPhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X. Lu, MD PhD, Carlyn Tan, MD, Donna Massey, MSN, RN, Meghan Salcedo, BSN, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Kathryn Ciardiello, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata D Yellapantula, Francesco Maura, MD, Tim J Peterson, PharmD, Andriy Derkach, PhD, Sean Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan L. Shah, MDMS, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

DOI: https://doi.org/10.1182/blood-2020-140152

Published: 2020

Journal Articles

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-136341

Published: 2020

Journal Articles

Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas

Brandon S. Imber, MD MA, Miguel-Angel Perales, MD, Jessica Flynn, BS, Josel D Ruiz, MPH, Sean Devlin, PhD, Ana Alarcon Tomas, MD, Carla Hajj, MD, Connie Lee Batlevi, MDPhD, Parastoo B. Dahi, MD, Richard J Lin, MDPhD, Jae H. Park, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Sergio A. Giralt, MD, Craig S. Sauter, MD, M. Lia Palomba, MD, Joachim Yahalom, MD

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-140991

Published: 2020

Journal Articles

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Trent Wang, DO,MPH, Michael Scordo, MD, Kwang Woo Ahn, PhD, Stella Chen, MS, Mohamed A. Kharfan-Dabaja, MDMBA, Alex F. Herrera, MD, Mehdi Hamadani, MD, Craig S. Sauter, MD

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-137237

Published: 2020

Journal Articles

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Michael Scordo, MD, Lihua E Budde, MD PhD, Mehrdad Abedi, MD, Carolyn Mulroney, MD, Bita Fakhri, MDMPH, Attaphol Pawarode, MDPhD, Bhagirathbhai Dholaria, MBBS, Edward Kavalerchik, MD, Sanjay K. Aggarwal, MD, Muzaffar H. Qazilbash, MD, Paul Finnegan, MD, Sergio A. Giralt, MD

Blood (2020) 136 (Supplement 1): 14–15.

DOI: https://doi.org/10.1182/blood-2020-137257

Published: 2020

Journal Articles

VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup

Carlyn Tan, MD, Benjamin Diamond, MD, Malin Hultcrantz, MD PhD, Neha Korde, MD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Dhwani Patel, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

DOI: https://doi.org/10.1182/blood-2020-141988

Published: 2020

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Carlyn Tan, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Benjamin Diamond, MD, Meghan Salcedo, RN, Kelly Werner, RN, Jenna Rispoli, RN, Julia Caple, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Isabel Concepcion, NP, Ciardello Amanda, MS, Aisara Chansakul, BS, Julia Schlossman, BA, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Angela Harrison, MS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata Yellapantula, PhD, Francesco Maura, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Neha Korde, MD

Blood (2020) 136 (Supplement 1): 7.

DOI: https://doi.org/10.1182/blood-2020-142466

Published: 2020

Journal Articles

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Blood (2020) 136 (Supplement 1): 8–10.

DOI: https://doi.org/10.1182/blood-2020-141131

Published: 2020

Journal Articles

Compliments to complement blockade for TA-TMA

Michael Scordo, Sergio Giralt

Blood (2020) 135 (13): 981–983.

DOI: https://doi.org/10.1182/blood.2020005040

Published: 2020

2 3

NARROW

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma

Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center

Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Compliments to complement blockade for TA-TMA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only